PPIDT00083
Drug Information
| Name | Octreotide |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB00104 |
| Type | biotech |
| Indication | Octreotide by injection is used for the treatment of acromegaly and the reduction of flushing and diarrhea symptoms related to carcinoid tumors and/or vasoactive intestinal peptide (VIPoma) tumors.[L14513] The delayed-release oral formulation is used for the long-term treatment of acromegaly in patients who tolerate and respond adequately to injectable octreotide and [lanreotide].[L14507,L45528] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Solution | Parenteral |
50.0 mcg
|
| Suspension | Parenteral |
20.000 mg
|
| Injection | Subcutaneous |
2.5 mg/1mL
|
| Solution | Subcutaneous |
0.200 mg
|
| Solution | Parenteral |
1 mg
|
| Solution | Parenteral |
1.000 mg
|
| Solution | Parenteral |
1.000 g
|
| Injection, powder, for suspension | Parenteral |
10 MG/2ML
|
| Injection, powder, for suspension | Parenteral |
10 MG
|
| Injection, powder, for suspension | Parenteral |
20 MG
|
| Injection, powder, for suspension | Parenteral |
20 MG/2ML
|
| Injection, powder, for suspension | Parenteral |
30 MG/2ML
|
| Injection, powder, for suspension | Parenteral |
30 MG
|
| Injection, solution | — |
100 MICROGRAMMI/1ML
|
| Injection, solution | — |
100 MICROGRAMMI/ML
|
| Injection, solution | — |
1000 MICROGRAMMI/5ML
|
| Injection, solution | — |
50 MICROGRAMMI/ML
|
| Injection, solution | — |
50 MICROGRAMMI/1ML
|
| Injection, solution | — |
500 MICROGRAMMI/1ML
|
| Injection, solution | — |
500 MICROGRAMMI/ML
|
| Capsule, delayed release | Oral |
20 mg
|
| Capsule, delayed release | Oral |
20 mg/1
|
| Solution | Parenteral |
0.2 mg
|
| Injection | — |
0.1 mg
|
| Injection | — |
0.111 mg
|
| Injection | Intravenous |
1000 ug/1mL
|
| Injection | Intravenous |
200 ug/1mL
|
| Injection | Intravenous; Subcutaneous |
100 ug/1mL
|
| Injection | Intravenous; Subcutaneous |
1000 ug/1mL
|
| Injection | Intravenous; Subcutaneous |
200 ug/1mL
|
| Injection | Intravenous; Subcutaneous |
50 ug/1mL
|
| Injection | Intravenous; Subcutaneous |
500 ug/1mL
|
| Injection, solution | Intravenous |
200 ug/1mL
|
| Injection, solution | Intravenous; Subcutaneous |
100 ug/1mL
|
| Injection, solution | Intravenous; Subcutaneous |
1000 ug/1mL
|
| Injection, solution | Intravenous; Subcutaneous |
200 ug/1mL
|
| Injection, solution | Intravenous; Subcutaneous |
50 ug/1mL
|
| Injection, solution | Intravenous; Subcutaneous |
500 ug/1mL
|
| Powder | Not applicable |
1 g/1g
|
| Solution | Intravenous; Subcutaneous |
100 mcg / mL
|
| Solution | Intravenous; Subcutaneous |
50 mcg / mL
|
| Solution | Intravenous; Subcutaneous |
500 mcg / mL
|
| Injection, solution | Parenteral |
0.05 MG/ML
|
| Injection, solution | Parenteral |
0.1 MG/ML
|
| Injection, solution | Parenteral |
0.5 MG/ML
|
| Injection, solution | Parenteral |
1 MG/5ML
|
| Injection, powder, for suspension, extended release; kit | Intramuscular |
10 mg / vial
|
| Injection, powder, for suspension, extended release; kit | Intramuscular |
20 mg / vial
|
| Injection, powder, for suspension, extended release; kit | Intramuscular |
30 mg / vial
|
| Injection, solution | Parenteral |
0.2 MG/ML
|
| Injection, solution | Parenteral |
0.05 MG/1ML
|
| Injection, solution | Parenteral |
0.1 MG/1ML
|
| Injection, solution | Parenteral |
0.5 MG/1ML
|
| Injection, powder, for suspension, extended release | Intramuscular |
10 MG/vial
|
| Injection, powder, for suspension, extended release | Intramuscular |
20 MG/vial
|
| Injection, powder, for suspension, extended release | Intramuscular |
30 MG/vial
|
| Injection | Intravenous; Subcutaneous |
|
| Injection, powder, for suspension | — |
|
| Injection, solution | — |
|
| Injection | Intravenous; Subcutaneous |
0.1 MG/ML
|
| Solution | Intravenous; Subcutaneous |
200 mcg / mL
|
| Solution | — |
0.1 mg/1ml
|
| Solution | — |
0.5 mg/1ml
|
| Injection, solution | Intravenous |
0.1 mg/ml
|
| Injection, solution | Parenteral |
100 Mikrogramm/ml
|
| Injection, solution | Parenteral |
|
| Injection, solution | Parenteral |
50 Mikrogramm/ml
|
| Injection, solution | Parenteral |
500 Mikrogramm/ml
|
| Solution | Parenteral |
0.05 mg
|
| Solution | Parenteral |
0.1 mg
|
| Injection | Intravenous |
0.5 mg/ml
|
| Injection | Intravenous |
0.1 mg/ml
|
| Injection | Subcutaneous |
0.05 mg/ml
|
| Injection | Subcutaneous |
0.1 mg/ml
|
| Injection, powder, for solution | Intramuscular |
10 mg
|
| Injection, powder, for solution | Intramuscular |
20 mg
|
| Injection, powder, for solution | Intramuscular |
30 mg
|
| Injection, powder, for suspension, extended release | Intramuscular |
10 mg / vial
|
| Injection, powder, for suspension, extended release | Intramuscular |
20 mg / vial
|
| Injection, powder, for suspension, extended release | Intramuscular |
30 mg / vial
|
| Powder | — |
10 mg/1vial
|
| Injection, suspension | — |
10 mg
|
| Injection, suspension | — |
20 mg
|
| Powder | — |
20 mg/1vial
|
| Powder | — |
30 mg/1vial
|
| Injection, suspension | — |
30 mg
|
| Injection, powder, for suspension; kit | Intramuscular |
1.667 mg/1mL
|
| Injection, powder, for suspension; kit | Intramuscular |
3.33 mg/1mL
|
| Injection, powder, for suspension; kit | Intramuscular |
5 mg/1mL
|
| Kit | Intramuscular |
1.667 mg/1mL
|
| Kit | Intramuscular |
10 mg/1
|
| Kit | Intramuscular |
20 mg/1
|
| Kit | Intramuscular |
3.33 mg/1mL
|
| Kit | Intramuscular |
30 mg/1
|
| Kit | Intramuscular |
5 mg/1mL
|
| Injection | Intramuscular |
10 mg
|
| Injection | Intramuscular |
20 mg
|
| Injection | Intramuscular |
30 mg
|
| Injection | Parenteral |
0.2 mg
|
| Solution | Intravenous; Subcutaneous |
0.1 mg
|
| Injection, powder, for suspension | Intramuscular |
3000000 mg
|
| Injection, powder, for suspension | Intramuscular |
2000000 mg
|
| Injection, solution | — |
1 MG/5ML
|
| Injection, solution | Parenteral |
100 ug/ml
|
| Injection, solution | Parenteral |
500 ug/ml
|
| Solution | Parenteral |
0.200 mg
|
| Suspension | Parenteral |
11.200 mg
|
| Solution | Parenteral |
1.00 mg
|
| Injection, powder, lyophilized, for solution | Intravenous; Subcutaneous |
200 cg
|
| Injection, solution | Parenteral |
200 MICROGRAMMI/ML
|
| Injection, solution | Parenteral |
100 MICROGRAMMI/ML
|
| Injection, solution | Parenteral |
500 MICROGRAMMI/ML
|
| Injection, solution | — |
0.1 mg/1ml
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| target | P30874 | SSTR2 | Somatostatin receptor type 2 | Homo sapiens | binder | Link |
| enzyme | P05164 | MPO | Myeloperoxidase | Homo sapiens | inhibitor | Link |
| enzyme | P08684 | CYP3A4 | Cytochrome P450 3A4 | Homo sapiens | inhibitor | Link |
| transporter | P08183 | ABCB1 | ATP-dependent translocase ABCB1 | Homo sapiens | substrate | Link |
| transporter | Q92887 | ABCC2 | ATP-binding cassette sub-family C member 2 | Homo sapiens | substrate|inhibitor | Link |
| carrier | P02768 | ALB | Albumin | Homo sapiens | binder | Link |